Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M104Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-6.7
Enterprise Value $M96.1EPS (TTM) $-0.8Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book32.210-y EBITDA Growth Rate %-3.5Quick Ratio4.2Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-1.0Current Ratio4.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-190.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M34.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GALT is held by these investors:



GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.6783.23view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.6783.23view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.6585.45view
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.6585.45view
Greenberg ArthurDirector 2016-01-05Buy1,666$1.7277.91view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.145.71view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$253view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.5320.95view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.713.33view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-17.07view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent f Apr 25 2017 
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congr Apr 18 2017 
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update Mar 28 2017 
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU Mar 23 2017 
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Busin Mar 21 2017 
GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic De Mar 14 2017 
Galectin Therapeutics to Present at 29th Annual ROTH Conference Mar 09 2017 
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis Mar 06 2017 
Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" Oct 06 2015 

More From Other Websites
Can The Uptrend Continue for Galectin Therapeutics (GALT)? Apr 28 2017
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent... Apr 25 2017
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Apr 24 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Apr 20 2017
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? Apr 20 2017
ResMed (RMD) Q3 Earnings: Disappointment in the Cards? Apr 18 2017
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store? Apr 18 2017
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver... Apr 18 2017
Can Illumina (ILMN) Spring a Surprise this Earnings Season? Apr 17 2017
5 Drug Stocks That Could Be Big Winners this Earnings Season Apr 17 2017
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store? Apr 13 2017
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store? Apr 12 2017
Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Apr 11 2017
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7% Apr 10 2017
Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News Apr 03 2017
Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Mar 30 2017
Edited Transcript of GALT earnings conference call or presentation 28-Mar-17 1:00pm GMT Mar 29 2017
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update Mar 28 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)